Market Overview

Akorn Shares Rally Following Increased Price Target

Related AKRX
Benzinga's Top Upgrades
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks

Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.

The note cited a "game changing" effect if Akorn matches Taro Pharmaceutical Industries' recent price increases in topical generics.

Shares are currently up 5.25 percent at $34.99.

Latest Ratings for AKRX

Sep 2016PiperJaffrayUpgradesNeutralOverweight
Aug 2016Deutsche BankDowngradesBuyHold
Aug 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: NeedhamAnalyst Color News Price Target Analyst Ratings


Related Articles (AKRX)

View Comments and Join the Discussion!